一只涨450%，一只涨150%，这两家“凤凰之星”获奖公司做对了什么？

Core Insights - The significant stock price increases of Kangfang Biopharma and Pop Mart, exceeding 150% and 450% respectively, reflect the accurate predictions of the "2024 Phoenix Star Listed Company Awards" regarding high-quality companies [1][3][14] Company Performance - Kangfang Biopharma achieved a revenue of 1.412 billion yuan in the first half of 2025, marking a year-on-year growth of 33.7%, driven by the commercialization of core products [3][5] - Pop Mart reported a revenue of 13.88 billion yuan during the same period, with a remarkable year-on-year growth of 204.4%, showcasing its strong monetization capabilities in cultural IP operations [5][9] Strategic Initiatives - Both companies are actively pursuing globalization strategies to tap into overseas market potential, which is crucial for their scale expansion [5][6] - Kangfang Biopharma's key products, such as Cardunili and Yivosi, are being commercialized globally, with significant licensing agreements and clinical trials underway in the U.S. [5][9] - Pop Mart is adapting its international strategy by signing local artists and creating products tailored to regional consumer preferences, enhancing its global appeal [6][9] Industry Trends - The innovative pharmaceutical sector, where Kangfang Biopharma operates, is experiencing structural changes, including improved healthcare systems and accelerated drug approvals, contributing to the growth of Chinese innovative drug companies [9][10] - Pop Mart is capitalizing on the rise of the IP economy, driven by the increasing demand for emotional value consumption among Generation Z and the global popularity of "Guzi" culture [9][10] Evaluation Criteria - The "Phoenix Star" awards focus on companies' core competitiveness and long-term industry impact rather than short-term financial metrics, highlighting the potential for sustained growth [10][12] - The evaluation process includes data analysis, expert reviews, and public voting, ensuring a comprehensive assessment of companies' long-term value [10][12]